logo
logo

Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing To Power The Next Era Of Dna-Enabled Industries

Apr 11, 2022•over 3 years ago

Amount Raised

$68 Million

Round Type

series a

Description

Ansa Biotechnologies today announced it has closed an oversubscribed Series A financing round of $68 million led by Northpond Ventures, with participation from new investors RA Capital, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fiscus Ventures, PEAK6 Strategic Capital, Carbon Silicon Ventures, Codon Capital, and existing investors Mubadala Capital, Humboldt Fund, Fifty Years, and Horizons Ventures. The company has raised a total of $82 million from private financings to date.

Company Information

Company

Ansa Biotechnologies

About

Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that is faster, cleaner, and more accurate than existing methods. For more information, visit ansabio.com or follow on Twitter and LinkedIn.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech